Doctor-led aesthetics in Sutton Coldfield
MDr MaryamAesthetics

Polynucleotides

Polynucleotides with hyaluronic acid: why the formulation changes the evidence

Some injectable products combine polynucleotides with hyaluronic acid, so results from a hybrid formulation cannot be attributed to polynucleotides alone or applied to every product.

5 minute read

‘Polynucleotide treatment’ can describe different products

Polynucleotide injectables are often discussed as if they form one interchangeable category. In practice, products differ in concentration, molecular characteristics, intended area and instructions for use. Some contain polynucleotides alone, while others combine them with non-cross-linked or cross-linked hyaluronic acid and additional ingredients. Those differences can change the product’s behaviour, purpose and evidence.

Hyaluronic acid attracts water, but its clinical role depends on its formulation. A lightly structured skin-quality product is not the same as a cross-linked filler designed to create volume. When a study tests a combined product, any improvement may come from the polynucleotides, the hyaluronic acid, their interaction, the injection itself or several factors together.

What did the 2026 hybrid-filler study find?

A 2026 prospective study followed 15 adults with moderate-to-severe cheek volume loss after treatment with a hybrid filler containing hyaluronic acid and polynucleotides. At 4, 12 and 24 weeks, photographic assessments reported improved cheek volume. Measurements of water loss, hydration and elasticity also changed over time, and no serious adverse event was reported in this small group.

The study was open-label, took place at one centre and had no untreated or alternative-treatment control group. It therefore cannot show how much of the change came from either ingredient. Most importantly, it evaluated a volumising hybrid filler, so its findings should not be used to promise equivalent contour or skin-quality effects from a different polynucleotide injectable.

A combined acne-scar product raises the same question

Another 2026 prospective cohort treated 30 adults with moderate-to-severe atrophic acne scars using a product containing polynucleotides, hyaluronic acid and mannitol. Scar measurements improved on average over six months, but 30% of participants did not improve by the study’s scar-classification measure. There was no separate group receiving polynucleotides alone, hyaluronic acid alone or no treatment.

The authors also disclosed research grants and work with the corporate sponsor and other aesthetic-device producers. This does not make the findings invalid, but it is relevant when judging certainty. The study supports further research into that exact combined formulation; it does not isolate the contribution of polynucleotides or establish a universal acne-scar protocol.

Why product-specific evidence matters

A 2026 systematic review found only seven randomised PN and PDRN trials involving 183 participants across skin rejuvenation, scar prevention and wound healing. Products, treatment schedules and outcomes varied. Combining such studies may identify promising signals, but it cannot make every formulation equivalent or define the best product for a particular face, concern or skin condition.

A consultation should name the exact product and ingredients, clarify whether the goal is hydration, texture, scar improvement or volume, and explain which evidence actually matches that goal. It should also cover alternatives, the number and spacing of sessions, review arrangements and the possibility of little or no visible improvement.

Downtime and adverse effects depend on the whole formulation

Expected short-term effects can include stinging, tenderness, redness, swelling, small raised injection points, itching, pinpoint bleeding or bruising. A product intended to add volume may produce different swelling or tissue effects from a low-viscosity injectable. Rare complications may be serious, so increasing pain, spreading redness or heat, discharge, fever, unusual skin colour, marked swelling, eye pain or visual symptoms need prompt assessment.

The exact formulation, allergies—including fish allergy where relevant—medical conditions, medicines, previous reactions, pregnancy or breastfeeding, active infection or inflammation and planned procedures must be reviewed. A product that is suitable for one area or purpose may not be appropriate elsewhere. Treatment should follow its instructions rather than a protocol borrowed from a different study or brand.

Read beyond the category name

The useful question is not simply whether polynucleotides ‘work’. It is whether a particular formulation has credible evidence for the individual’s concern, whether the likely change is worthwhile and whether its risks and limitations are acceptable. GMC guidance requires honest discussion of evidence, uncertainties, alternatives and follow-up before a cosmetic intervention.

Product names can sound similar while the ingredients and intended effects differ. Asking to see the product information and discussing how closely the supporting study matches the proposed treatment helps avoid overgeneralising. No combined formulation should be assumed to deliver the benefits of every ingredient separately, and no study result can guarantee an individual outcome.

← Back to the journal

Personalised medical assessment

Questions about treatment?

Book a consultation to discuss your concerns, health and treatment options without pressure.

Free consultation – a £1 booking fee secures your appointment